Watts Gwilliam & Co., LLC Bio Line Rx Ltd. Transaction History
Watts Gwilliam & Co., LLC
- $474 Billion
- Q4 2024
A detailed history of Watts Gwilliam & Co., LLC transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Watts Gwilliam & Co., LLC holds 34,000 shares of BLRX stock, worth $3,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,000Holding current value
$3,740% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
3.37MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$95,3140.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$89,7254.05% of portfolio
-
Envestnet Asset Management Inc239KShares$26,3100.0% of portfolio
-
Morgan Stanley New York, NY198KShares$21,7290.0% of portfolio
-
Values First Advisors, Inc.198KShares$21,7260.06% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $6.77M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...